

BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email info.bmjpo@bmj.com

BMJ Paediatrics Open

Early Peanut Immunotherapy in Children (EPIC) trial: Protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2023-002294
Article Type:	Protocol
Date Submitted by the Author:	21-Sep-2023
Complete List of Authors:	O'Sullivan, Michael; Perth Children's Hospital, Immunology Department; The University of Western Australia, Medical School Bear, Natasha; Perth Children's Hospital, Immunology Department Metcalfe, Jessica; Perth Children's Hospital, Immunology Department; Telethon Kids Institute
Keywords:	Therapeutics

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Early Peanut Immunotherapy in Children (EPIC) trial: Protocol for a pragmatic**
4 **randomised controlled trial of peanut oral immunotherapy in children under 5 years of**
5 **age**
6
7

8 O'Sullivan M^{1,2}

9 Bear N¹

10 Metcalfe J^{1,3}

11
12
13
14 ¹Immunology Department, Perth Children's Hospital, Nedlands, Australia

15 ²University of Western Australia, Perth, Australia

16 ³Telethon Kids Institute, Nedlands, Australia
17
18

19 Author contributions: MO was primarily responsible for the study concept, protocol writing
20 and preparation of manuscript. JM contributed to study design and protocol writing. NB
21 prepared the statistical analysis plan for the protocol. All authors have reviewed and
22 approved the manuscript for submission. The authors have no conflicts of interest to declare.
23
24

25
26 Trial registration number ACTRN12621001001886 (Australian New Zealand Clinical Trials
27 Registry, anzctr.org.au)
28

29 Trial sponsor: Child and Adolescent Health Service, 15 Hospital Avenue, Nedlands WA
30 6009 Australia.
31
32

33 Protocol version 5, dated 19 July 2022
34
35

36 Funding information – Project funded by the Government of Western Australia Department
37 and Channel 7 Telethon Trust through the WA Child Research Fund
38
39

40 **Abstract**
41

42
43 **Introduction:** Food allergy is a major public health challenge in Australia. Despite
44 widespread uptake of infant feeding and allergy prevention guidelines the incidence of peanut
45 allergy in infants has not fallen, and prevalence of peanut allergy in school-aged children
46 continues to rise. Therefore, effective and accessible treatments for peanut allergy are
47 required. There is high quality evidence for efficacy of oral immunotherapy in 4-17 year old
48 children, however few randomised trials have investigated peanut OIT in young children.
49 Furthermore, the use of food products for OIT with doses prepared and administered by
50 parents without requiring pharmacy compounding has the potential to reduce costs associated
51 with the OIT product.
52
53
54
55

56 **Methods and analysis:** Early Peanut Immunotherapy in Children (EPIC) is an open label
57 randomised controlled trial of peanut OIT compared to standard care (avoidance) to induce
58 desensitisation in children 1-4 years old with peanut allergy. n=50 participants will be
59 randomised 1:1 to intervention (daily peanut OIT for 12 months) or control (peanut
60

1
2
3 avoidance). The primary outcome is the proportion of children in each group with a peanut
4 eliciting dose >600mg peanut protein as assessed by open peanut challenge after 12 months,
5 analysed by intention to treat. Secondary outcomes include safety as assessed by frequency
6 and severity of treatment-related adverse events, quality of life measured using age-
7 appropriate food allergy-specific questionnaires, and immunological changes during OIT.
8
9

10
11 **Ethics:** The trial is approved by the Child and Adolescent Health Service Human Research
12 Ethics Committee and prospectively registered with the Australia and New Zealand Clinical
13 Trials Registry.
14

15
16 **Dissemination:** Trial outcomes will be published in a peer-review journal and presented and
17 local and national scientific meetings.
18
19

20 **Introduction**

21
22
23 Food allergy is a major public health problem affecting one in ten Australian infants¹. Peanut
24 allergy is the most prevalent food allergy in children, affecting 2-3% of <5-year-olds and
25 usually persists to later in life¹⁻⁴. Children with peanut allergy are at risk of potentially life-
26 threatening anaphylaxis⁵ and have reduced quality of life^{6,7} that worsens on reaching school
27 age⁸ due to dietary, social and emotional impact⁹.
28
29

30
31 Despite uptake of infant feeding and allergy prevention guidelines in Australia, the incidence
32 of peanut allergy is unchanged¹⁰ and the prevalence of allergies in children¹¹ is rising, hence
33 effective treatments for peanut allergy are needed.
34

35
36 Oral immunotherapy is an emerging treatment for food allergy, involving daily ingestion of
37 increasing amounts of food allergen. There are two possible outcomes achieved with OIT;
38 desensitisation, which is a temporary suppression of allergic reaction while on OIT, and
39 sustained unresponsiveness, involving remission of allergy with long-term protection against
40 allergic reactions after stopping treatment. Most children receiving OIT for peanut allergy are
41 desensitised¹²⁻¹⁶ but fewer achieve remission^{17,18}. While remission is associated with a greater
42 long-term reduction in allergic reactions than desensitisation¹⁸, achieving a partially
43 desensitised state (i.e. establishing a relatively high eliciting dose of peanut consumption at
44 which an allergic reaction occurs) has been modelled to significantly reduce the likelihood of
45 peanut allergic reactions from accidental consumption¹⁹. This may lead to reduced food-
46 related anxiety and improved patient empowerment, however these benefits could be offset
47 by the burden of treatment hence further evaluation of OIT in clinical trials is required²⁰.
48
49
50
51
52

53
54 International expert guidelines recommended consideration of OIT for children with severe
55 allergy from 4 years of age²¹, but not in younger children. Furthermore, OIT is not
56 recommended by 2023 Australian expert guidelines due to uncertainty around efficacy, safety
57 and other patient-important outcomes that should be addressed in clinical trials²⁰.
58
59
60

1
2
3 A peanut OIT product, Palforzia, has demonstrated efficacy in children from 4 to 17 years old
4 after 12 months of treatment¹⁴ and has subsequently been approved by some medicines
5 regulators. Theoretical concerns have been raised about potential variability of food products
6 being used in OIT protocols, however consensus guidelines^{21,22} supported by published
7 data^{15,16} recommend OIT can be offered using food products while following standardised,
8 evidence-based protocols.
9
10

11
12 Administering OIT using readily available food products with doses prepared and
13 administered by parents, rather than compounded by pharmacy or dispensed by health
14 professionals, may improve access to OIT by reducing costs of treatment. However, it is
15 necessary to further investigate the efficacy, safety and tolerability of a pragmatic, food-
16 based peanut OIT treatment protocol prior to implementation in routine clinical practice.
17
18
19

20 This paper reports the research protocol for the Early Peanut Immunotherapy in Children
21 (EPIC) open-label randomised controlled trial evaluating the efficacy of peanut OIT (pOIT),
22 using caregiver-measured and administered doses of a supermarket food product, at inducing
23 desensitisation in children from 1-4 years of age when compared to standard care of strict
24 peanut avoidance.
25
26
27

28 **Aims**

29 **Primary objective**

30
31 To compare the proportion of participants with a peanut eliciting dose (ED) >600mg peanut
32 protein in pOIT and control groups, as assessed by open peanut oral food challenge (OFC) at
33 12 months (end of treatment, EOT).
34
35
36
37
38

39 **Secondary and exploratory objectives**

40
41 To describe the safety of pOIT as assessed by parent-reported treatment-related adverse
42 events and efficacy as assessed by range of EDs at EOT OFC; compare changes in quality of
43 life and perception of OIT between groups and during course of pOIT; and describe treatment
44 costs and immunological changes associated with pOIT.
45
46
47

48 **Methods**

49 **Trial design**

50
51 EPIC is a 2-armed, open-label, randomised controlled superiority trial of peanut oral
52 immunotherapy (pOIT) compared to peanut avoidance (1:1 allocation).
53
54
55
56

57 pOIT = peanut OIT taken daily for 12 months

58 Control = peanut avoidance (standard care, no placebo)
59
60

Study setting

This is a single centre study conducted in a tertiary paediatric hospital (Perth Children's Hospital, Australia). Food challenges and initiation of OIT will be conducted on a day admission ward, and up-dosing visits will be conducted in outpatient clinic under the supervision of experienced nursing staff with medical support as required. Between study visits, pOIT will be administered daily by parents at home.

Participants

Fifty children from 1 to 4 years of age with confirmed or highly probable IgE-mediated peanut allergy will be enrolled.

Inclusion criteria

- 1) Age from 1-4 years
- 2) Confirmed or highly probable peanut allergy, defined as
 - a) Confirmed: positive peanut SPT (mean wheal diameter ≥ 3 mm) or specific IgE (>0.35 kU/L) and objective allergic reaction to screening peanut open food challenge
 - b) Highly probable:
 - i) Unequivocal past clinical history of allergic reaction to peanut, and at least 1 of the following at screening: Peanut SPT mean wheal diameter at ≥ 8 mm ; Peanut sIgE >15 kU/L; Ara h 2 sIgE >1 kU/L, OR
 - ii) Equivocal or no clinical history of allergic reaction to peanut, with at least 2 of the following at screening: Peanut SPT at screening ≥ 8 mm; Peanut sIgE >15 kU/L; Ara h 2 sIgE >1 kU/L

Exclusion criteria

- 1) History of severe, life-threatening anaphylaxis to peanut prior to enrolment.
- 2) Use of beta-blockers
- 3) Currently receiving any other allergen (food, venom, aeroallergen) immunotherapy, or have received food immunotherapy in the past 3 months.
- 4) Significant underlying medical conditions that increase risk of adverse outcomes in the event of an allergic reaction, such as severe cardiovascular or respiratory diseases.
- 5) Persistent, uncontrolled asthma or wheezing episodes.

Recruitment and consent

Potential participants will be referred from public and private allergy clinics or recruited from the community. Informed consent will be obtained in accordance with International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) and National Health and Medical Research Council (NHMRC) guidelines and documented using Research Electronic

1
2
3 Data Capture (REDCap) software hosted on secure Western Australian Department of Health
4 servers.
5

6 7 **Blinding and Randomisation** 8

9
10 Participants will be randomised to pOIT or standard care (peanut avoidance), stratified by
11 confirmed or highly probable peanut allergy (as per inclusion criteria) and age (1-2 or 3-4
12 years old at enrolment).
13

14
15 This pragmatic study is unblinded with no placebo, reflecting current standard of care where
16 the alternative to peanut OIT is peanut avoidance.
17

18 19 **Intervention** 20

21
22 Peanut OIT consists of incrementally increasing daily doses of defatted peanut flour (50%
23 protein by weight, Peanut Butter & Co Pure Peanut powder, New York, USA). This is a
24 commercially available food grade supermarket product that does not require any specialised
25 manufacturing or handling.
26

27
28 Intervention (OIT) arm treatment protocol (see Table 1):
29

30
31 *Treatment initiation:* Participants receive up to 4 increasing doses every 20 minutes to reach a
32 final dose of 15mg peanut protein. Doses are mixed with a small amount of a food of the
33 participants' choice. If a participant has an allergic reaction during TI, the next day they
34 commence pOIT dosing at home with the dose immediately below the one that provoked onset
35 of symptoms (i.e. Dose 1-3). If all doses are tolerated during TI, participants commence pOIT
36 at home with 15mg of nut protein (Dose 4). Any remaining doses not completed during TI will
37 be incorporated into the up-dosing phase.
38
39

40
41 Participants' parents are provided with standard measuring spoons (1/64 to 1/4 teaspoons) to
42 dispense daily treatment doses. A suspension of peanut powder in water is prepared by parents
43 to administer doses ≤ 10 mg at home if required. Parents will receive training on use of
44 measuring spoons and preparation of suspension (if required) during TI and up-dosing visits.
45
46

47
48 *Up-dosing:* Following TI participants continue the same dose at home daily for 2 weeks. Up-
49 dosing to the next dose level occurs under clinical supervision in an outpatient setting, with 2
50 hours of observation post-dose. If the increased dose is tolerated, participants continue that
51 dose at home; if there is an allergic reaction during the up-dosing visit, participants will restart
52 the previously tolerated dose at home from the following day. Up-dosing will occur every 2
53 weeks (minimum 6 visits) until the target maintenance dose of 360mg peanut protein (3/8 tsp
54 peanut powder) is reached.
55
56

57
58 *Maintenance:* Participants will continue to take daily doses of 3/8 tsp peanut flour until a total
59 of 12 months of treatment is completed (calculated from date of TI visit). Participants can miss
60

up to 2 non-consecutive doses per week to accommodate requirements of daily life (daycare, sports, school). Dose modifications may be made through this phase according to pre-specified criteria for moderate-severe treatment-related allergic reactions, intercurrent illnesses, or extended periods of missed doses.

Treatment Phase	Dose Level	Defatted peanut flour dose	Equivalent Peanut Protein	Interval prior to dose increase
Treatment Initiation (Single day if tolerated)	1	2mg	1 mg	N/A
	2	6mg	3 mg	20 min
	3	20mg	10 mg	20 min
	4	1/64 tsp	15 mg	2 weeks
Up-dosing	5	1/32 tsp	30 mg	2 weeks
	6	1/16 tsp	60 mg	2 weeks
	7	1/8 tsp	120 mg	2 weeks
	8	3/16 tsp	180 mg	2 weeks
	9	1/4 tsp	240mg	2 weeks
Maintenance	10	3/8 tsp	360mg	Until 52 weeks total treatment

Table 1: Peanut OIT dosing schedule

Control (standard care) arm

Continued strict avoidance of peanut for 12 months from the date of randomisation.

Primary outcome

Proportion of participants with a peanut eliciting dose > 600mg peanut protein at end of treatment in pOIT vs control, as assessed by open peanut OFC. The primary outcome will be assessed by conducting a peanut OFC with peanut at end of treatment, defined as 12 months after Treatment Initiation in the pOIT group and 12 months after randomisation in the control group.

Secondary outcomes

Patient-reported outcomes

- Proportion of participants reporting, severity of, and frequency of, treatment-related adverse events
- Change in child (Food Allergy Quality of Life Questionnaire – Parent Form, FAQLQ-PF) and parent (Food Allergy Quality of Life – Parental Burden, FAQL-PB) quality of life and parent food allergy self-efficacy (Food Allergy Self-Efficacy for Parents, FASE-P) from baseline to EOT

Other secondary outcomes

- Proportion of participants discontinuing peanut OIT treatment
- Change in peanut specific IgE and peanut SPT wheal size from baseline to EOT
- Proportion of participants with (a) eliciting dose ≥ 300 mg, (b) eliciting dose ≥ 600 mg, and (c) no allergic reaction to 2500mg peanut protein dose at EOT

Exploratory outcomes

Patient-reported

- Change in quality of life and parent self-efficacy during pOIT (baseline vs 12 weeks and 24 weeks; 12 weeks and 24 weeks vs EOT)
- Parental perceptions of OIT before, during and after treatment, as assessed by Net Promoter Score (NPS) and Patient Experience Survey (PES)

Other exploratory outcomes

- Baseline characteristics associated with successful desensitisation following pOIT
- Changes in peanut SPT and sIgE in responders and non-responders to pOIT
- Changes in other immune parameters (humoral, RNA/protein expression, cellular phenotype) associated with pOIT
- Treatment-associated costs of pOIT

Study procedures

The Schedules of Procedures are summarised in Tables 2 (Intervention) and 3 (Control).

Baseline assessment

Demographics, personal and family history of atopic disease including participant history of allergic reactions to peanut and other medical history.

Eczema will be assessed using the SCORing of Atopic Dermatitis (SCORAD) scoring index²³.

Medications

Beta-blockers, anti-IgE monoclonal antibodies and any other form of allergen immunotherapy will be prohibited.

All participants will be prescribed an adrenaline autoinjector and ASCIA Action Plan for Anaphylaxis.

Biospecimen collection

Blood: Venous blood will be drawn in lithium heparin and serum vacutainer tubes. Peanut and Ara h 2 serum sIgE will be measured by ImmunoCAP (Phadia AB, Uppsala, Sweden). Whole blood will be separated for frozen storage of aliquots peripheral blood mononuclear cells (stored in liquid nitrogen), plasma and serum (stored at -80 degrees C).

1
2
3
4 *Stool:* Samples will be collected at baseline and EOT using OMNIgene GUT kit.
5
6

7 *Saliva:* Saliva samples will be collected using a cotton swab, centrifuged and frozen.
8
9

10 Skin Prick Test (SPT)

11
12 Peanut extract (ALK USA) plus negative saline and positive histamine control SPT will be
13 conducted on the forearm of each participant, using Quintips. The average of the longest wheal
14 diameter (D1) and the longest perpendicular measurement to D1 will be recorded as the mean
15 wheal diameter.
16
17

18 **Quality of Life (QoL) and Parental Perception Questionnaires**

19
20 The FAQLQ and FAQL-PB are disease specific health-related QoL for children with food
21 allergy²⁴ and their parents²⁵. The Food Allergy Self-Efficacy for Parents (FASE-P) is a
22 validated questionnaire to assess parental confidence in managing food allergy²⁶. QoL will be
23 measured using FAQLQ-PF²⁷, FAQL-PB and FASE-P completed by the same parent
24 throughout..
25
26
27

28
29 Parental perceptions of OIT will be measured using NPS, a widely used customer experience
30 metric that has been used to assess patient satisfaction with health services²⁸.
31
32

33
34 The Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional
35 Distress Anxiety Short Form 8a^{29,30} and the Parent Proxy Short Form 8a³¹ questionnaires are
36 validated person-centered measures for anxiety in individuals and their children. Parents will
37 complete this questionnaire once at EOS.
38
39

40
41 The PES is derived from the Australian Hospital Patient Experience Question Set³²
42 developed by the Australian Commission on Safety and Quality in Health Care, modified to
43 suit the trial setting and with additional questions included based on feedback from consumer
44 consultation prior to the trial.
45
46

47 **Daily Diary**

48
49 Parents will complete a web-based daily electronic diary directly into REDCap. Diary data
50 will be used to assess adherence, AEs, accidental peanut ingestion and hospital admissions.
51 Control group will complete a daily diary during Month 3 and Month 9 to collect background
52 rates of parent-reported AEs.
53
54
55

56 **Oral food challenge**

57
58 An open peanut OFC will be performed at study entry for those participants who do not meet
59 the criteria for “highly probable peanut allergy”, and in all participants at end of treatment. The
60

OFC will be conducted using an adaptation of the ASCIA peanut challenge protocol, modified to include an additional 600mg dose step resulting in increments of 10mg, 30mg, 100mg, 300mg, 600mg, 1000mg and 2500mg peanut protein given at 20-minute intervals.

Positive challenges will be defined by an allergic reaction meeting PRACTALL consensus stopping criteria³³ with severity assessed in accordance with published multidisciplinary expert consensus guidelines³⁴. The eliciting dose (ED) is defined as the amount of peanut protein in the OFC dose given immediately prior to onset of signs meeting stopping criteria.

Statistical analysis plan

Sample size

A sample size of 50 randomised participants allocated 1:1 to pOIT (n=25) or control (n=25) will have power of 0.85 to detect a difference in proportion achieving the primary outcome of 66% in pOIT and 25% in control with an alpha of 0.05.

Baseline assumptions of pOIT efficacy were derived from published registry data of preschool pOIT outcomes³⁵ and a phase III RCT of peanut OIT in 4-17-year-olds³⁶. The estimated 25% response rate in controls includes participants with naturally high (>600mg peanut protein) reaction threshold, spontaneous resolution of allergy, or rarely misclassification at baseline of a non-allergic participant as having “highly probable” peanut allergy, noting that those with relatively low sIgE and SPT would not be eligible for enrolment in this study based without undergoing an OFC at entry to confirm peanut allergy.

Outcome analysis

Continuous variables will be presented as mean and standard deviations or medians and interquartile ranges depending on distribution of data. For count data rates will be reported, while categorical variables will be presented as frequencies and proportions. For exploratory variables statistical analyses will be hypothesis generating to inform future studies.

Alpha will be set at 0.05, and 95% confidence intervals (CIs) reported unless otherwise specified. We will perform between group comparisons for each primary and secondary outcome at the end of the study at 12 months. Efficacy will be determined by comparing differences between groups using a Chi Square test or a Fishers Exact test (if expected cell counts <5), with difference in proportions reported. Odds ratios will be produced via logistic regression, with adjustment for potential confounders. Secondary outcomes with continuous data (peanut SPT wheal size and sIgE) will be analysed using Student t-tests or Mann-Whitney U test depending on distribution.

Adverse events will be presented in frequency tables. Exposure-adjusted incidence of treatment-related AEs will be calculated by dividing total trAEs by total pOIT doses taken over a specified period.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Analysis will primarily be on all consented participants in an intention-to-treat analysis. Per-protocol analysis will include only children who complete the study as per the protocol. Deidentified data will be used for outcome analysis.

No interim analysis is planned.

Research Ethics Approval

The study has been reviewed by the Child and Adolescent Health Service HREC (RGS 4384).

Study oversight, registration, funding, consumer involvement and dissemination

A consumer reference group comprising parents of preschool aged children with peanut allergy were consulted when developing the study protocol.

The Child and Adolescent Health Service will be the study Sponsor.

The trial was prospectively registered with the Australia New Zealand Clinical Trials Registry (ACTRN12621001001886).

An independent data and safety monitoring committee (DSMC) will be comprised of a biostatistician, and two clinical immunologists who have no conflicts of interest with this study.

This work is supported by the Government of Western Australia Department of Health and Channel 7 Telethon Trust through the WA Child Research Fund. The funders have no role in the study design, conduct or analysis.

Results will be published in a peer-reviewed journal and presented at national scientific meetings using grouped and deidentified data only. A consumer reference group, comprising parents of preschool aged children with peanut allergy, were consulted when developing the study protocol and will inform the plan for dissemination of outcomes to participants and the community.

PEANUT OIT; Intervention Group							
Study phase	Screening		Treatment			End of treatment	End of Study
Week of study	Up to -24		0	2 to 12	16 to 48	52 (up to 56)	+4 from EOT
Visit category	Screening visit	Entry OFC	Initiation	Up-dosing	Maintenance	Exit OFC	
Duration	2 hours	5-6 hours	4 hours	2-3 hours	15 mins remote	5-6 hours	15min remote
Procedure							
Informed consent	X						
Eligibility criteria	X	X	X				
Demographics, medical and family history	X						
Anthropometrics, vital signs, physical exam, SCORAD	X	X	X	X		X	
Questionnaires	X			X - 12 weeks	X - 24 weeks		X
Skin prick test	X					X	
Blood, stool and saliva samples	X	(X)		X - 12 weeks		X	
Oral food challenge		X				X	
Adverse event, concomitant medication assessment		X	X	X	X	X	X
Anaphylaxis education		X	X	X		X	
OIT doses at site			X	X			
OIT dosing education			X	X			

Table 2: Summary of schedule of procedures for intervention group

PEANUT OIT; Intervention Group					
Study phase	Screening		Standard care	End of treatment	End of Study
Week of study	Up to -24		0-52	52 (up to 56)	+4 from EOT
Visit category	Screening visit	Entry OFC	Telephone contact every 3 months	Exit OFC	
Duration	2 hours	5-6 hours	15 mins remote	5-6 hours	15min remote
Procedure					
Informed consent	X				
Eligibility criteria	X	X			
Demographics, medical and family history	X				
Anthropometrics, vital signs, physical exam, SCORAD	X	X		X	
Questionnaires	X		X - 12 weeks and 24 weeks		X
Skin prick test	X			X	
Blood, stool and saliva samples	X	(X)		X	
Oral food challenge		X		X	
Adverse event, concomitant medication assessment		X	X	X	X
Anaphylaxis education		X		X	
Strict peanut avoidance			X		

Table 3: Summary of schedule of procedures for control group

References

1. Osborne NJ, Koplin JJ, Martin PE, et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. *J Allergy Clin Immunol* 2011; **127**(3): 668-76.e2.
2. Peters RL, Allen KJ, Dharmage SC, et al. Natural history of peanut allergy and predictors of resolution in the first 4 years of life: A population-based assessment. *J Allergy Clin Immunol* 2015; **135**(5): 1257-66 e1-2.
3. Peters RL, Koplin JJ, Gurrin LC, et al. The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up. *J Allergy Clin Immunol* 2017; **140**(1): 145-53.e8.
4. Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA. The natural history of peanut allergy. *J Allergy Clin Immunol* 2001; **107**(2): 367-74.
5. Mullins RJ, Wainstein BK, Barnes EH, Liew WK, Campbell DE. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. *Clinical & Experimental Allergy* 2016; **46**(8): 1099-110.
6. Avery NJ, King RM, Knight S, Hourihane JO. Assessment of quality of life in children with peanut allergy. *Pediatr Allergy Immunol* 2003; **14**(5): 378-82.
7. Venter C, Sommer I, Moonesinghe H, et al. Health-related quality of life in children with perceived and diagnosed food hypersensitivity. *Pediatr Allergy Immunol* 2015; **26**(2): 126-32.
8. Thörnqvist V, Middelveld R, Wai HM, et al. Health-related quality of life worsens by school age amongst children with food allergy. *Clinical and Translational Allergy* 2019; **9**(1).
9. Lieberman JA, Gupta RS, Knibb RC, et al. The global burden of illness of peanut allergy: A comprehensive literature review. *Allergy* 2021; **76**(5): 1367-84.
10. Soriano VX, Peters RL, Moreno-Betancur M, et al. Association Between Earlier Introduction of Peanut and Prevalence of Peanut Allergy in Infants in Australia. *JAMA* 2022; **328**(1): 48.
11. Tang MLK, Mullins RJ. Food allergy: is prevalence increasing? *Internal Medicine Journal* 2017; **47**(3): 256-61.
12. Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. *J Allergy Clin Immunol* 2017; **139**(1): 173-81 e8.
13. Tang ML, Ponsonby AL, Orsini F, et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. *J Allergy Clin Immunol* 2015; **135**(3): 737-44 e8.
14. Investigators PGoC, Vickery BP, Vereda A, et al. AR101 Oral Immunotherapy for Peanut Allergy. *N Engl J Med* 2018; **379**(21): 1991-2001.
15. de Silva D, Rodriguez Del Rio P, de Jong NW, et al. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis. *Allergy* 2022; **77**(6): 1852-62.
16. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. *Lancet* 2019; **393**(10187): 2222-32.
17. Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. *The Lancet* 2022; **399**(10322): 359-71.

18. Loke P, Orsini F, Lozinsky AC, et al. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. *Lancet Child Adolesc Health* 2022; **6**(3): 171-84.
19. Remington BC, Krone T, Kim EH, et al. Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy. *Annals of Allergy, Asthma & Immunology* 2019; **123**(5): 488-93.e2.
20. Australasian Society of Clinical Immunology and Allergy. Position Paper - Oral Immunotherapy for Food Allergy, 2023. Available at <https://www.allergy.org.au/hp/papers/ascia-oral-immunotherapy-for-food-allergy> [Accessed 17 July 2023].
21. Muraro A, De Silva D, Halken S, et al. Managing food allergy: GA2LEN guideline 2022. *World Allergy Organization Journal* 2022; **15**(9): 100687.
22. Bégin P, Chan ES, Kim H, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. *Allergy Asthma Clin Immunol* 2020; **16**: 20.
23. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. *Dermatology* 1997; **195**(1): 10-9.
24. Cohen BL, Noone S, Muñoz-Furlong A, Sicherer SH. Development of a questionnaire to measure quality of life in families with a child with food allergy. *J Allergy Clin Immunol* 2004; **114**(5): 1159-63.
25. Knibb RC, Stalker C. Validation of the Food Allergy Quality of Life-Parental Burden Questionnaire in the UK. *Qual Life Res* 2013; **22**(7): 1841-9.
26. Knibb RC, Barnes C, Stalker C. Parental confidence in managing food allergy: development and validation of the Food Allergy Self-Efficacy Scale for Parents (FASE-P). *Clin Exp Allergy* 2015; **45**(11): 1681-9.
27. Dunngalvin A, De Blokfloksstra BMJ, Burks AW, Dubois AEJ, Hourihane JOB. Food allergy QoL questionnaire for children aged 0–12 years: content, construct, and cross-cultural validity. *Clinical & Experimental Allergy* 2008; **38**(6): 977-86.
28. Alismail A, Schaeffer B, Oh A, et al. The Use of the Net Promoter Score (NPS) in an Outpatient Allergy and Pulmonary Clinic: An Innovative Look into Using Tablet-Based Tool vs Traditional Survey Method. *Patient Related Outcome Measures* 2020; **Volume 11**: 137-42.
29. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. *Journal of Clinical Epidemiology* 2010; **63**(11): 1179-94.
30. Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D. Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS®): Depression, Anxiety, and Anger. *Assessment* 2011; **18**(3): 263-83.
31. Irwin DE, Gross HE, Stucky BD, et al. Development of six PROMIS pediatrics proxy-report item banks. *Health and Quality of Life Outcomes* 2012; **10**(1): 22.
32. Australian Commission on Safety and Quality in Health Care. Australian Hospital Patient Experience Question Set. 2019. Available at <https://www.safetyandquality.gov.au/our-work/indicators-measurement-and-reporting/australian-hospital-patient-experience-question-set> [Accessed 17 July 2023]
33. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma &

1
2
3 Immunology-European Academy of Allergy and Clinical Immunology PRACTALL
4 consensus report. *J Allergy Clin Immunol* 2012; **130**(6): 1260-74.

5 34. Dribin TE, Schnadower D, Spergel JM, et al. Severity grading system for acute
6 allergic reactions: A multidisciplinary Delphi study. *J Allergy Clin Immunol* 2021; **148**(1):
7 173-81.

8 35. Soller L, Abrams EM, Carr S, et al. First Real-World Effectiveness Analysis of
9 Preschool Peanut Oral Immunotherapy. *The Journal of Allergy and Clinical Immunology: In*
10 *Practice* 2020.

11 36. The PALISADE Group of Clinical Investigators. AR101 Oral Immunotherapy for
12 Peanut Allergy. *N Engl J Med* 2018; **379**(21): 1991-2001.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Paediatrics Open

Early Peanut Immunotherapy in Children (EPIC) trial: Protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2023-002294.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Oct-2023
Complete List of Authors:	O'Sullivan, Michael; Perth Children's Hospital; The University of Western Australia Bear, Natasha; Perth Children's Hospital Metcalfe, Jessica; Perth Children's Hospital; Telethon Kids Institute
Keywords:	Therapeutics

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Early Peanut Immunotherapy in Children (EPIC) trial: Protocol for a pragmatic**
4 **randomised controlled trial of peanut oral immunotherapy in children under 5 years of**
5 **age**
6
7

8 O'Sullivan, Michael David^{1,2}

9 Bear, Natasha¹

10 Metcalfe, Jessica^{1,3}

11
12
13 ¹Perth Children's Hospital, Nedlands, WA, Australia

14 ²The University of Western Australia, Perth, WA, Australia

15 ³Telethon Kids Institute, Nedlands, WA, Australia
16
17
18

19 Author contributions: MO was primarily responsible for the study concept, protocol writing
20 and preparation of manuscript. JM contributed to study design and protocol writing. NB
21 prepared the statistical analysis plan for the protocol. All authors have reviewed and
22 approved the manuscript for submission. The authors have no conflicts of interest to declare.
23
24

25 Trial registration number ACTRN12621001001886 (Australian New Zealand Clinical Trials
26 Registry, anzctr.org.au)
27
28

29 Trial sponsor: Child and Adolescent Health Service, 15 Hospital Avenue, Nedlands WA
30 6009 Australia.
31
32

33 Protocol version 5, dated 19 July 2022
34
35

36 Funding information – Project funded by the Government of Western Australia Department
37 and Channel 7 Telethon Trust through the WA Child Research Fund
38
39

40 **Abstract**
41

42
43 **Introduction:** Food allergy is a major public health challenge in Australia. Despite
44 widespread uptake of infant feeding and allergy prevention guidelines the incidence of peanut
45 allergy in infants has not fallen, and prevalence of peanut allergy in school-aged children
46 continues to rise. Therefore, effective and accessible treatments for peanut allergy are
47 required. There is high quality evidence for efficacy of oral immunotherapy in 4-17 year old
48 children, however few randomised trials have investigated peanut OIT in young children.
49 Furthermore, the use of food products for OIT with doses prepared and administered by
50 parents without requiring pharmacy compounding has the potential to reduce costs associated
51 with the OIT product.
52
53
54
55

56 **Methods and analysis:** Early Peanut Immunotherapy in Children (EPIC) is an open label
57 randomised controlled trial of peanut OIT compared to standard care (avoidance) to induce
58 desensitisation in children 1-4 years old with peanut allergy. n=50 participants will be
59 randomised 1:1 to intervention (daily peanut OIT for 12 months) or control (peanut
60

1
2
3 avoidance). The primary outcome is the proportion of children in each group with a peanut
4 eliciting dose >600mg peanut protein as assessed by open peanut challenge after 12 months,
5 analysed by intention to treat. Secondary outcomes include safety as assessed by frequency
6 and severity of treatment-related adverse events, quality of life measured using age-
7 appropriate food allergy-specific questionnaires, and immunological changes during OIT.
8
9

10
11 **Ethics:** The trial is approved by the Child and Adolescent Health Service Human Research
12 Ethics Committee and prospectively registered with the Australia and New Zealand Clinical
13 Trials Registry.
14

15
16 **Dissemination:** Trial outcomes will be published in a peer-review journal and presented and
17 local and national scientific meetings.
18
19

20 **Key Messages**

21 **What is already known on this topic**

22
23 Oral immunotherapy (OIT) is recognised as a treatment option for 4-17-year-old children
24 with peanut allergy that is effective at inducing desensitisation, with some studies also
25 demonstrating improved quality of life. However, there is less data on outcomes of OIT in
26 younger children and no published randomised controlled trials of food-based peanut OIT
27 compared to avoidance in preschoolers.
28
29

30 **What this study hopes to add**

31
32 This study aims to demonstrate that a pragmatic food-based peanut OIT protocol using
33 parent-measured doses is safe and effective at inducing desensitisation, while improving
34 quality of life during the first 12 months of treatment compared to standard care (peanut
35 avoidance).
36
37

38 **How this study might affect research, practice or policy**

39
40 This study may support the implementation of peanut OIT in clinical practice for young
41 children using a translatable, non-pharmaceutical intervention by providing the evidence for
42 improved patient-important outcomes of OIT compared to existing standard of care of peanut
43 avoidance.
44

45 **Introduction**

46
47 Food allergy is a major public health problem affecting one in ten Australian infants.[1] Peanut
48 allergy is the most prevalent food allergy in children, affecting 2-3% of <5-year-olds and
49 usually persists to later in life.[1-4] Children with peanut allergy are at risk of potentially life-
50 threatening anaphylaxis[5] and have reduced quality of life[6, 7] that worsens on reaching
51 school age[8] due to dietary, social and emotional impact.[9]
52
53

54
55 Despite uptake of infant feeding and allergy prevention guidelines in Australia, the incidence
56 of peanut allergy is unchanged[10] and the prevalence of allergies in children[11] is rising,
57 hence effective treatments for peanut allergy are needed.
58
59
60

1
2
3 Oral immunotherapy is an emerging treatment for food allergy, involving daily ingestion of
4 increasing amounts of food allergen. There are two possible outcomes achieved with OIT;
5 desensitisation, which is a temporary suppression of allergic reaction while on OIT, and
6 sustained unresponsiveness, involving remission of allergy with long-term protection against
7 allergic reactions after stopping treatment. Most children receiving OIT for peanut allergy are
8 desensitised[12-16] but fewer achieve remission.[17, 18] While remission is associated with a
9 greater long-term reduction in allergic reactions than desensitisation,[18] achieving a partially
10 desensitised state (i.e. establishing a relatively high eliciting dose of peanut consumption at
11 which an allergic reaction occurs) has been modelled to significantly reduce the likelihood of
12 peanut allergic reactions from accidental consumption.[19] This may lead to reduced food-
13 related anxiety and improved patient empowerment, however these benefits could be offset
14 by the burden of treatment hence further evaluation of OIT in clinical trials is required.[20]
15
16
17
18
19

20 International expert guidelines recommended consideration of OIT for children with severe
21 allergy from 4 years of age,[21] but not in younger children. Furthermore, OIT is not
22 recommended by 2023 Australian expert guidelines due to uncertainty around efficacy, safety
23 and other patient-important outcomes that should be addressed in clinical trials.[20]
24
25
26
27

28 A peanut OIT product, Palforzia, has demonstrated efficacy in children from 4 to 17 years old
29 after 12 months of treatment[14] and has subsequently been approved by some medicines
30 regulators. Theoretical concerns have been raised about potential variability of food products
31 being used in OIT protocols, however consensus guidelines[21, 22] supported by published
32 data[15, 16] recommend OIT can be offered using food products while following
33 standardised, evidence-based protocols.
34
35
36
37

38 Administering OIT using readily available food products with doses prepared and
39 administered by parents, rather than compounded by pharmacy or dispensed by health
40 professionals, may improve access to OIT by reducing costs of treatment. However, it is
41 necessary to further investigate the efficacy, safety and tolerability of a pragmatic, food-
42 based peanut OIT treatment protocol prior to implementation in routine clinical practice.
43
44
45

46 This paper reports the research protocol for the Early Peanut Immunotherapy in Children
47 (EPIC) open-label randomised controlled trial evaluating the efficacy of peanut OIT (pOIT),
48 using caregiver-measured and administered doses of a supermarket food product, at inducing
49 desensitisation in children from 1-4 years of age when compared to standard care of strict
50 peanut avoidance.
51
52

53 **Aims**

54 **Primary objective**

55
56
57
58
59
60

To compare the proportion of participants with a peanut eliciting dose (ED) >600mg peanut protein in pOIT and control groups, as assessed by open peanut oral food challenge (OFC) at 12 months (end of treatment, EOT).

Secondary and exploratory objectives

To describe the safety of pOIT as assessed by parent-reported treatment-related adverse events and efficacy as assessed by range of EDs at EOT OFC; compare changes in quality of life and perception of OIT between groups and during course of pOIT; and describe treatment costs and immunological changes associated with pOIT.

Methods

Trial design

EPIC is a 2-armed, open-label, randomised controlled superiority trial of peanut oral immunotherapy (pOIT) compared to peanut avoidance (1:1 allocation).

pOIT = peanut OIT taken daily for 12 months

Control = peanut avoidance (standard care, no placebo)

Study setting

This is a single centre study conducted in a tertiary paediatric hospital (Perth Children's Hospital, Australia). Food challenges and initiation of OIT will be conducted on a day admission ward, and up-dosing visits will be conducted in outpatient clinic under the supervision of experienced nursing staff with medical support as required. Between study visits, pOIT will be administered daily by parents at home.

Participants

Fifty children from 1 to 4 years of age with confirmed or highly probable IgE-mediated peanut allergy will be enrolled.

Inclusion criteria

- 1) Age from 1-4 years
- 2) Confirmed or highly probable peanut allergy, defined as
 - a) Confirmed: positive peanut SPT (mean wheal diameter ≥ 3 mm) or specific IgE (>0.35 kU/L) and objective allergic reaction to screening peanut open food challenge
 - b) Highly probable:

- i) Unequivocal past clinical history of allergic reaction to peanut, and at least 1 of the following at screening: Peanut SPT mean wheal diameter at ≥ 8 mm ; Peanut sIgE >15 kU/L; Ara h 2 sIgE >1 kU/L, OR
- ii) Equivocal or no clinical history of allergic reaction to peanut, with at least 2 of the following at screening: Peanut SPT at screening ≥ 8 mm; Peanut sIgE >15 kU/L; Ara h 2 sIgE >1 kU/L

Exclusion criteria

- 1) History of severe, life-threatening anaphylaxis to peanut prior to enrolment.
- 2) Use of beta-blockers
- 3) Currently receiving any other allergen (food, venom, aeroallergen) immunotherapy, or have received food immunotherapy in the past 3 months.
- 4) Significant underlying medical conditions that increase risk of adverse outcomes in the event of an allergic reaction, such as severe cardiovascular or respiratory diseases.
- 5) Persistent, uncontrolled asthma or wheezing episodes.

Recruitment and consent

Potential participants will be referred from public and private allergy clinics or recruited from the community. Informed consent will be obtained in accordance with International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) and National Health and Medical Research Council (NHMRC) guidelines and documented using Research Electronic Data Capture (REDCap) software hosted on secure Western Australian Department of Health servers.

Blinding and Randomisation

Participants will be randomised to pOIT or standard care (peanut avoidance), stratified by confirmed or highly probable peanut allergy (as per inclusion criteria) and age (1-2 or 3-4 years old at enrolment).

This pragmatic study is unblinded with no placebo, reflecting current standard of care where the alternative to peanut OIT is peanut avoidance.

Intervention

Peanut OIT consists of incrementally increasing daily doses of defatted peanut flour (50% protein by weight, Peanut Butter & Co Pure Peanut powder, New York, USA). This is a commercially available food grade supermarket product that does not require any specialised manufacturing or handling.

Intervention (OIT) arm treatment protocol (see Table 1):

Treatment initiation: Participants receive up to 4 increasing doses every 20 minutes to reach a final dose of 15mg peanut protein. Doses are mixed with a small amount of a food of the participants' choice. If a participant has an allergic reaction during TI, the next day they commence pOIT dosing at home with the dose immediately below the one that provoked onset of symptoms (i.e. Dose 1-3). If all doses are tolerated during TI, participants commence pOIT at home with 15mg of nut protein (Dose 4). Any remaining doses not completed during TI will be incorporated into the up-dosing phase.

Participants' parents are provided with standard measuring spoons (1/64 to 1/4 teaspoons) to dispense daily treatment doses. A suspension of peanut powder in water is prepared by parents to administer doses ≤ 10 mg at home if required. Parents will receive training on use of measuring spoons and preparation of suspension (if required) during TI and up-dosing visits.

Up-dosing: Following TI participants continue the same dose at home daily for 2 weeks. Up-dosing to the next dose level occurs under clinical supervision in an outpatient setting, with 2 hours of observation post-dose. If the increased dose is tolerated, participants continue that dose at home; if there is an allergic reaction during the up-dosing visit, participants will restart the previously tolerated dose at home from the following day. Up-dosing will occur every 2 weeks (minimum 6 visits) until the target maintenance dose of 360mg peanut protein (3/8 tsp peanut powder) is reached.

Maintenance: Participants will continue to take daily doses of 3/8 tsp peanut flour until a total of 12 months of treatment is completed (calculated from date of TI visit). Participants can miss up to 2 non-consecutive doses per week to accommodate requirements of daily life (daycare, sports, school). Dose modifications may be made through this phase according to pre-specified criteria for moderate-severe treatment-related allergic reactions, intercurrent illnesses, or extended periods of missed doses.

Treatment Phase	Dose Level	Defatted peanut flour dose	Equivalent Peanut Protein	Interval prior to dose increase
Treatment Initiation (Single day if tolerated)	1	2mg	1 mg	N/A
	2	6mg	3 mg	20 min
	3	20mg	10 mg	20 min
	4	1/64 tsp	15 mg	2 weeks
Up-dosing	5	1/32 tsp	30 mg	2 weeks
	6	1/16 tsp	60 mg	2 weeks
	7	1/8 tsp	120 mg	2 weeks
	8	3/16 tsp	180 mg	2 weeks
	9	1/4 tsp	240mg	2 weeks
Maintenance	10	3/8 tsp	360mg	Until 52 weeks total treatment

Table 1: Peanut OIT dosing schedule

Control (standard care) arm

Continued strict avoidance of peanut for 12 months from the date of randomisation.

Primary outcome

Proportion of participants with a peanut eliciting dose > 600mg peanut protein at end of treatment in pOIT vs control, as assessed by open peanut OFC. The primary outcome will be assessed by conducting a peanut OFC with peanut at end of treatment, defined as 12 months after Treatment Initiation in the pOIT group and 12 months after randomisation in the control group.

Secondary outcomes

Patient-reported outcomes

- Proportion of participants reporting, severity of, and frequency of, treatment-related adverse events
- Change in child (Food Allergy Quality of Life Questionnaire – Parent Form, FAQLQ-PF) and parent (Food Allergy Quality of Life – Parental Burden, FAQL-PB) quality of life and parent food allergy self-efficacy (Food Allergy Self-Efficacy for Parents, FASE-P) from baseline to EOT

Other secondary outcomes

- Proportion of participants discontinuing peanut OIT treatment
- Change in peanut specific IgE and peanut SPT wheal size from baseline to EOT
- Proportion of participants with (a) eliciting dose ≥ 300 mg, (b) eliciting dose ≥ 600 mg, and (c) no allergic reaction to 2500mg peanut protein dose at EOT

Exploratory outcomes

Patient-reported

- Change in quality of life and parent self-efficacy during pOIT (baseline vs 12 weeks and 24 weeks; 12 weeks and 24 weeks vs EOT)
- Parental perceptions of OIT before, during and after treatment, as assessed by Net Promoter Score (NPS) and Patient Experience Survey (PES)

Other exploratory outcomes

- Baseline characteristics associated with successful desensitisation following pOIT
- Changes in peanut SPT and sIgE in responders and non-responders to pOIT
- Changes in other immune parameters (humoral, RNA/protein expression, cellular phenotype) associated with pOIT
- Treatment-associated costs of pOIT

Study procedures

The Schedules of Procedures are summarised in Tables 2 (Intervention) and 3 (Control).

Baseline assessment

Demographics, personal and family history of atopic disease including participant history of allergic reactions to peanut and other medical history.

Eczema will be assessed using the SCORing of Atopic Dermatitis (SCORAD) scoring index[23].

Medications

Beta-blockers, anti-IgE monoclonal antibodies and any other form of allergen immunotherapy will be prohibited.

All participants will be prescribed an adrenaline autoinjector and ASCIA Action Plan for Anaphylaxis.

Biospecimen collection

Blood: Venous blood will be drawn in lithium heparin and serum vacutainer tubes. Peanut and Ara h 2 serum sIgE will be measured by ImmunoCAP (Phadia AB, Uppsala, Sweden). Whole blood will be separated for frozen storage of aliquots peripheral blood mononuclear cells (stored in liquid nitrogen), plasma and serum (stored at -80 degrees C).

Stool: Samples will be collected at baseline and EOT using OMNIgene GUT kit.

Saliva: Saliva samples will be collected using a cotton swab, centrifuged and frozen.

Skin Prick Test (SPT)

Peanut extract (ALK USA) plus negative saline and positive histamine control SPT will be conducted on the forearm of each participant, using Quintips. The average of the longest wheal diameter (D1) and the longest perpendicular measurement to D1 will be recorded as the mean wheal diameter.

Quality of Life (QoL) and Parental Perception Questionnaires

The FAQLQ and FAQL-PB are disease specific health-related QoL for children with food allergy[24] and their parents.[25] The Food Allergy Self-Efficacy for Parents (FASE-P) is a validated questionnaire to assess parental confidence in managing food allergy.[26] QoL will be measured using FAQLQ-PF,[27] FAQL-PB and FASE-P completed by the same parent throughout.

1
2
3 Parental perceptions of OIT will be measured using NPS, a widely used customer experience
4 metric that has been used to assess patient satisfaction with health services.[28]
5
6

7 The Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional
8 Distress Anxiety Short Form 8a[29, 30] and the Parent Proxy Short Form 8a[31]
9 questionnaires are validated person-centred measures for anxiety in individuals and their
10 children. Parents will complete this questionnaire once at EOS.
11
12

13 The PES is derived from the Australian Hospital Patient Experience Question Set[32]
14 developed by the Australian Commission on Safety and Quality in Health Care, modified to
15 suit the trial setting and with additional questions included based on feedback from consumer
16 consultation prior to the trial.
17
18

19 20 **Daily Diary** 21

22 Parents will complete a web-based daily electronic diary directly into REDCap. Diary data
23 will be used to assess adherence, AEs, accidental peanut ingestion and hospital admissions.
24 Control group will complete a daily diary during Month 3 and Month 9 to collect background
25 rates of parent-reported AEs.
26
27

28 29 **Oral food challenge** 30

31 An open peanut OFC will be performed at study entry for those participants who do not meet
32 the criteria for “highly probable peanut allergy”, and in all participants at end of treatment. The
33 OFC will be conducted using an adaptation of the ASCIA peanut challenge protocol, modified
34 to include an additional 600mg dose step resulting in increments of 10mg, 30mg, 100mg,
35 300mg, 600mg, 1000mg and 2500mg peanut protein given at 20-minute intervals.
36
37

38 Positive challenges will be defined by an allergic reaction meeting PRACTALL consensus
39 stopping criteria[33] with severity assessed in accordance with published multidisciplinary
40 expert consensus guidelines.[34] The eliciting dose (ED) is defined as the amount of peanut
41 protein in the OFC dose given immediately prior to onset of signs meeting stopping criteria.
42
43

44 45 **Statistical analysis plan** 46

47 48 Sample size 49

50 A sample size of 50 randomised participants allocated 1:1 to pOIT (n=25) or control (n=25)
51 will have power of 0.85 to detect a difference in proportion achieving the primary outcome of
52 66% in pOIT and 25% in control with an alpha of 0.05. Recruitment and randomisation of the
53 target participant sample size has been completed.
54
55

56 Baseline assumptions of pOIT efficacy were derived from published registry data of
57 preschool pOIT outcomes[35] and a phase III RCT of peanut OIT in 4-17-year-olds.[36] The
58
59
60

1
2
3 estimated 25% response rate in controls includes participants with naturally high (>600mg
4 peanut protein) reaction threshold, spontaneous resolution of allergy, or rarely
5 misclassification at baseline of a non-allergic participant as having “highly probable” peanut
6 allergy, noting that those with relatively low sIgE and SPT would not be eligible for
7 enrolment in this study based without undergoing an OFC at entry to confirm peanut allergy.
8
9

10 11 Outcome analysis

12
13
14 Continuous variables will be presented as mean and standard deviations or medians and
15 interquartile ranges depending on distribution of data. For count data rates will be reported,
16 while categorical variables will be presented as frequencies and proportions. For exploratory
17 variables statistical analyses will be hypothesis generating to inform future studies.
18
19

20
21 Alpha will be set at 0.05, and 95% confidence intervals (CIs) reported unless otherwise
22 specified. We will perform between group comparisons for each primary and secondary
23 outcome at the end of the study at 12 months. Efficacy will be determined by comparing
24 differences between groups using a Chi Square test or a Fishers Exact test (if expected cell
25 counts <5), with difference in proportions reported. Odds ratios will be produced via logistic
26 regression, with adjustment for potential confounders. Secondary outcomes with continuous
27 data (peanut SPT wheal size and sIgE) will be analysed using Student t-tests or Mann-Whitney
28 U test depending on distribution.
29
30

31
32 Adverse events will be presented in frequency tables. Exposure-adjusted incidence of
33 treatment-related AEs will be calculated by dividing total trAEs by total pOIT doses taken over
34 a specified period.
35
36

37
38 Analysis will primarily be on all consented participants in an intention-to-treat analysis. Per-
39 protocol analysis will include only children who complete the study as per the protocol.
40 Deidentified data will be used for outcome analysis.
41
42

43 No interim analysis is planned.
44

45 **Research Ethics Approval**

46
47
48 The study has been reviewed by the Child and Adolescent Health Service HREC (RGS 4384).
49
50

51 **Study oversight, registration, funding, consumer involvement and dissemination**

52
53 A consumer reference group comprising parents of preschool aged children with peanut allergy
54 were consulted when developing the study protocol.
55
56

57 The Child and Adolescent Health Service will be the study Sponsor.
58
59
60

1
2
3 The trial was prospectively registered with the Australia New Zealand Clinical Trials Registry
4 (ACTRN12621001001886).
5
6

7 An independent data and safety monitoring committee (DSMC) will be comprised of a
8 biostatistician, and two clinical immunologists who have no conflicts of interest with this study.
9
10

11 This work is supported by the Government of Western Australia Department of Health and
12 Channel 7 Telethon Trust through the WA Child Research Fund. The funders have no role in
13 the study design, conduct or analysis.
14
15

16 Results will be published in a peer-reviewed journal and presented at national scientific
17 meetings using grouped and deidentified data only. A consumer reference group, comprising
18 parents of preschool aged children with peanut allergy, were consulted when developing the
19 study protocol and will inform the plan for dissemination of outcomes to participants and the
20 community.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PEANUT OIT; Intervention Group							
Study phase	Screening		Treatment			End of treatment	End of Study
Week of study	Up to -24		0	2 to 12	16 to 48	52 (up to 56)	+4 from EOT
Visit category	Screening visit	Entry OFC	Initiation	Up-dosing	Maintenance	Exit OFC	
Duration	2 hours	5-6 hours	4 hours	2-3 hours	15 mins remote	5-6 hours	15min remote
Procedure							
Informed consent	X						
Eligibility criteria	X	X	X				
Demographics, medical and family history	X						
Anthropometrics, vital signs, physical exam, SCORAD	X	X	X	X		X	
Questionnaires	X			X - 12 weeks	X - 24 weeks		X
Skin prick test	X					X	
Blood, stool and saliva samples	X	(X)		X - 12 weeks		X	
Oral food challenge		X				X	
Adverse event, concomitant medication assessment		X	X	X	X	X	X
Anaphylaxis education		X	X	X		X	
OIT doses at site			X	X			
OIT dosing education			X	X			

Table 2: Summary of schedule of procedures for intervention group

PEANUT OIT; Intervention Group					
Study phase	Screening		Standard care	End of treatment	End of Study
Week of study	Up to -24		0-52	52 (up to 56)	+4 from EOT
Visit category	Screening visit	Entry OFC	Telephone contact every 3 months	Exit OFC	
Duration	2 hours	5-6 hours	15 mins remote	5-6 hours	15min remote
Procedure					
Informed consent	X				
Eligibility criteria	X	X			
Demographics, medical and family history	X				
Anthropometrics, vital signs, physical exam, SCORAD	X	X		X	
Questionnaires	X		X - 12 weeks and 24 weeks		X
Skin prick test	X			X	
Blood, stool and saliva samples	X	(X)		X	
Oral food challenge		X		X	
Adverse event, concomitant medication assessment		X	X	X	X
Anaphylaxis education		X		X	
Strict peanut avoidance			X		

Table 3: Summary of schedule of procedures for control group

References

1. Osborne NJ, Koplin JJ, Martin PE, et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. *J Allergy Clin Immunol* 2011; **127**(3): 668-76.
2. Peters RL, Allen KJ, Dharmage SC, et al. Natural history of peanut allergy and predictors of resolution in the first 4 years of life: A population-based assessment. *J Allergy Clin Immunol* 2015; **135**(5): 1257-66 e1-2.
3. Peters RL, Koplin JJ, Gurrin LC, et al. The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up. *J Allergy Clin Immunol* 2017; **140**(1): 145-53.e8.
4. Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA. The natural history of peanut allergy. *J Allergy Clin Immunol* 2001; **107**(2): 367-74.
5. Mullins RJ, Wainstein BK, Barnes EH, Liew WK, Campbell DE. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. *Clinical & Experimental Allergy* 2016; **46**(8): 1099-110.
6. Avery NJ, King RM, Knight S, Hourihane JO. Assessment of quality of life in children with peanut allergy. *Pediatr Allergy Immunol* 2003; **14**(5): 378-82.
7. Venter C, Sommer I, Moonesinghe H, et al. Health-related quality of life in children with perceived and diagnosed food hypersensitivity. *Pediatr Allergy Immunol* 2015; **26**(2): 126-32.
8. Thörnqvist V, Middelveld R, Wai HM, et al. Health-related quality of life worsens by school age amongst children with food allergy. *Clinical and Translational Allergy* 2019; **9**(1): 10.
9. Lieberman JA, Gupta RS, Knibb RC, et al. The global burden of illness of peanut allergy: A comprehensive literature review. *Allergy* 2021; **76**(5): 1367-84.
10. Soriano VX, Peters RL, Moreno-Betancur M, et al. Association Between Earlier Introduction of Peanut and Prevalence of Peanut Allergy in Infants in Australia. *JAMA* 2022; **328**(1): 48.
11. Tang MLK, Mullins RJ. Food allergy: is prevalence increasing? *Internal Medicine Journal* 2017; **47**(3): 256-61.
12. Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. *J Allergy Clin Immunol* 2017; **139**(1): 173-81 e8.
13. Tang ML, Ponsonby AL, Orsini F, et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. *J Allergy Clin Immunol* 2015; **135**(3): 737-44 e8.
14. Investigators PGoC, Vickery BP, Vereda A, et al. AR101 Oral Immunotherapy for Peanut Allergy. *N Engl J Med* 2018; **379**(21): 1991-2001.
15. de Silva D, Rodriguez Del Rio P, de Jong NW, et al. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis. *Allergy* 2022; **77**(6): 1852-62.
16. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. *Lancet* 2019; **393**(10187): 2222-32.
17. Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. *The Lancet* 2022; **399**(10322): 359-71.

18. Loke P, Orsini F, Lozinsky AC, et al. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. *Lancet Child Adolesc Health* 2022; **6**(3): 171-84.
19. Remington BC, Krone T, Kim EH, et al. Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy. *Annals of Allergy, Asthma & Immunology* 2019; **123**(5): 488-93.e2.
20. Australasian Society of Clinical Immunology and Allergy. Position Paper - Oral Immunotherapy for Food Allergy, 2023. Available at <https://www.allergy.org.au/hp/papers/ascia-oral-immunotherapy-for-food-allergy> [Accessed 17 July 2023].
21. Muraro A, De Silva D, Halken S, et al. Managing food allergy: GA2LEN guideline 2022. *World Allergy Organization Journal* 2022; **15**(9): 100687.
22. Bégin P, Chan ES, Kim H, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. *Allergy Asthma Clin Immunol* 2020; **16**: 20.
23. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. *Dermatology* 1997; **195**(1): 10-9.
24. Cohen BL, Noone S, Muñoz-Furlong A, Sicherer SH. Development of a questionnaire to measure quality of life in families with a child with food allergy. *J Allergy Clin Immunol* 2004; **114**(5): 1159-63.
25. Knibb RC, Stalker C. Validation of the Food Allergy Quality of Life-Parental Burden Questionnaire in the UK. *Qual Life Res* 2013; **22**(7): 1841-9.
26. Knibb RC, Barnes C, Stalker C. Parental confidence in managing food allergy: development and validation of the Food Allergy Self-Efficacy Scale for Parents (FASE-P). *Clin Exp Allergy* 2015; **45**(11): 1681-9.
27. Dunngalvin A, De Blokfloksstra BMJ, Burks AW, Dubois AEJ, Hourihane JOB. Food allergy QoL questionnaire for children aged 0–12 years: content, construct, and cross-cultural validity. *Clin Exp Allergy* 2008; **38**(6): 977-86.
28. Alismail A, Schaeffer B, Oh A, et al. The Use of the Net Promoter Score (NPS) in an Outpatient Allergy and Pulmonary Clinic: An Innovative Look into Using Tablet-Based Tool vs Traditional Survey Method. *Patient Related Outcome Measures* 2020; **Volume 11**: 137-42.
29. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. *Journal of Clinical Epidemiology* 2010; **63**(11): 1179-94.
30. Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D. Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS®): Depression, Anxiety, and Anger. *Assessment* 2011; **18**(3): 263-83.
31. Irwin DE, Gross HE, Stucky BD, et al. Development of six PROMIS pediatrics proxy-report item banks. *Health and Quality of Life Outcomes* 2012; **10**(1): 22.
32. Australian Commission on Safety and Quality in Health Care. Australian Hospital Patient Experience Question Set. 2019. Available at <https://www.safetyandquality.gov.au/our-work/indicators-measurement-and-reporting/australian-hospital-patient-experience-question-set> [Accessed 17 July 2023]
33. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma &

1
2
3 Immunology-European Academy of Allergy and Clinical Immunology PRACTALL
4 consensus report. *J Allergy Clin Immunol* 2012; **130**(6): 1260-74.

5 34. Dribin TE, Schnadower D, Spergel JM, et al. Severity grading system for acute
6 allergic reactions: A multidisciplinary Delphi study. *J Allergy Clin Immunol* 2021; **148**(1):
7 173-81.

8 35. Soller L, Abrams EM, Carr S, et al. First Real-World Effectiveness Analysis of
9 Preschool Peanut Oral Immunotherapy. *J Allergy Clin Immunol Pract* 2021; **9**(3):1349-1356.

10 36. The PALISADE Group of Clinical Investigators. AR101 Oral Immunotherapy for
11 Peanut Allergy. *N Engl J Med* 2018; **379**(21): 1991-2001.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Paediatrics Open

Early Peanut Immunotherapy in Children (EPIC) trial: Protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2023-002294.R2
Article Type:	Protocol
Date Submitted by the Author:	08-Oct-2023
Complete List of Authors:	O'Sullivan, Michael; Perth Children's Hospital; The University of Western Australia Bear, Natasha; Perth Children's Hospital Metcalfe, Jessica; Perth Children's Hospital; Telethon Kids Institute
Keywords:	Therapeutics

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Early Peanut Immunotherapy in Children (EPIC) trial: Protocol for a pragmatic**
4 **randomised controlled trial of peanut oral immunotherapy in children under 5 years of**
5 **age**
6
7

8 O'Sullivan, Michael David^{1,2}

9 Bear, Natasha¹

10 Metcalfe, Jessica^{1,3}

11
12
13 ¹Perth Children's Hospital, Nedlands, WA, Australia

14 ²The University of Western Australia, Perth, WA, Australia

15 ³Telethon Kids Institute, Nedlands, WA, Australia
16
17
18

19 Corresponding Author email address: michael.osullivan@research.uwa.edu.au
20
21

22 Author contributions: MO was primarily responsible for the study concept, protocol writing
23 and preparation of manuscript. JM contributed to study design and protocol writing. NB
24 prepared the statistical analysis plan for the protocol. All authors have reviewed and
25 approved the manuscript for submission. The authors have no conflicts of interest to declare.
26
27

28 Trial registration number ACTRN12621001001886 (Australian New Zealand Clinical Trials
29 Registry, anzctr.org.au)
30
31

32 Trial sponsor: Child and Adolescent Health Service, 15 Hospital Avenue, Nedlands WA
33 6009 Australia.
34
35

36 Protocol version 5, dated 19 July 2022
37
38

39 Funding information – Project funded by the Government of Western Australia Department
40 and Channel 7 Telethon Trust through the WA Child Research Fund
41
42

43 **Abstract**
44

45 **Introduction:** Food allergy is a major public health challenge in Australia. Despite
46 widespread uptake of infant feeding and allergy prevention guidelines the incidence of peanut
47 allergy in infants has not fallen, and prevalence of peanut allergy in school-aged children
48 continues to rise. Therefore, effective and accessible treatments for peanut allergy are
49 required. There is high quality evidence for efficacy of oral immunotherapy in 4-17 year old
50 children, however few randomised trials have investigated peanut OIT in young children.
51 Furthermore, the use of food products for OIT with doses prepared and administered by
52 parents without requiring pharmacy compounding has the potential to reduce costs associated
53 with the OIT product.
54
55
56
57

58 **Methods and analysis:** Early Peanut Immunotherapy in Children (EPIC) is an open label
59 randomised controlled trial of peanut OIT compared to standard care (avoidance) to induce
60

1
2
3 desensitisation in children 1-4 years old with peanut allergy. n=50 participants will be
4 randomised 1:1 to intervention (daily peanut OIT for 12 months) or control (peanut
5 avoidance). The primary outcome is the proportion of children in each group with a peanut
6 eliciting dose >600mg peanut protein as assessed by open peanut challenge after 12 months,
7 analysed by intention to treat. Secondary outcomes include safety as assessed by frequency
8 and severity of treatment-related adverse events, quality of life measured using age-
9 appropriate food allergy-specific questionnaires, and immunological changes during OIT.
10
11
12

13
14 **Ethics:** The trial is approved by the Child and Adolescent Health Service Human Research
15 Ethics Committee and prospectively registered with the Australia and New Zealand Clinical
16 Trials Registry.
17
18

19 **Dissemination:** Trial outcomes will be published in a peer-review journal and presented and
20 local and national scientific meetings.
21
22

23 **Key Messages**

24 **What is already known on this topic**

25
26 Oral immunotherapy (OIT) is recognised as a treatment option for 4-17-year-old children
27 with peanut allergy that is effective at inducing desensitisation, with some studies also
28 demonstrating improved quality of life. However, there is less data on outcomes of OIT in
29 younger children and no published randomised controlled trials of food-based peanut OIT
30 compared to avoidance in preschoolers.
31
32

33 **What this study hopes to add**

34
35 This study aims to evaluate the safety and effect of a pragmatic food-based peanut OIT
36 protocol using parent-measured doses, including impact on quality of life, during the first 12
37 months of treatment compared to standard care (peanut avoidance).
38
39

40 **How this study might affect research, practice or policy**

41
42 This study may support the implementation of peanut OIT in clinical practice for young
43 children using a translatable, non-pharmaceutical intervention by providing the evidence for
44 improved patient-important outcomes of OIT compared to existing standard of care of peanut
45 avoidance.
46

47 **Introduction**

48
49 Food allergy is a major public health problem affecting one in ten Australian infants.[1] Peanut
50 allergy is the most prevalent food allergy in children, affecting 2-3% of <5-year-olds and
51 usually persists to later in life.[1-4] Children with peanut allergy are at risk of potentially life-
52 threatening anaphylaxis[5] and have reduced quality of life[6, 7] that worsens on reaching
53 school age[8] due to dietary, social and emotional impact.[9]
54
55

56
57 Despite uptake of infant feeding and allergy prevention guidelines in Australia, the incidence
58 of peanut allergy is unchanged[10] and the prevalence of allergies in children[11] is rising,
59 hence effective treatments for peanut allergy are needed.
60

1
2
3
4
5 Oral immunotherapy is an emerging treatment for food allergy, involving daily ingestion of
6 increasing amounts of food allergen. There are two possible outcomes achieved with OIT;
7 desensitisation, which is a temporary suppression of allergic reaction while on OIT, and
8 sustained unresponsiveness, involving remission of allergy with long-term protection against
9 allergic reactions after stopping treatment. Most children receiving OIT for peanut allergy are
10 desensitised[12-16] but fewer achieve remission.[17, 18] While remission is associated with a
11 greater long-term reduction in allergic reactions than desensitisation,[18] achieving a partially
12 desensitised state (i.e. establishing a relatively high eliciting dose of peanut consumption at
13 which an allergic reaction occurs) has been modelled to significantly reduce the likelihood of
14 peanut allergic reactions from accidental consumption.[19] This may lead to reduced food-
15 related anxiety and improved patient empowerment, however these benefits could be offset
16 by the burden of treatment hence further evaluation of OIT in clinical trials is required.[20]
17
18
19
20

21
22 International expert guidelines recommended consideration of OIT for children with severe
23 allergy from 4 years of age,[21] but not in younger children. Furthermore, OIT is not
24 recommended by 2023 Australian expert guidelines due to uncertainty around efficacy, safety
25 and other patient-important outcomes that should be addressed in clinical trials.[20]
26
27
28
29

30
31 A peanut OIT product, Palforzia, has demonstrated efficacy in children from 4 to 17 years old
32 after 12 months of treatment[14] and has subsequently been approved by some medicines
33 regulators. Theoretical concerns have been raised about potential variability of food products
34 being used in OIT protocols, however consensus guidelines[21, 22] supported by published
35 data[15, 16] recommend OIT can be offered using food products while following
36 standardised, evidence-based protocols.
37
38

39
40 Administering OIT using readily available food products with doses prepared and
41 administered by parents, rather than compounded by pharmacy or dispensed by health
42 professionals, may improve access to OIT by reducing costs of treatment. However, it is
43 necessary to further investigate the efficacy, safety and tolerability of a pragmatic, food-
44 based peanut OIT treatment protocol prior to implementation in routine clinical practice.
45
46

47
48 This paper reports the research protocol for the Early Peanut Immunotherapy in Children
49 (EPIC) open-label randomised controlled trial evaluating the efficacy of peanut OIT (pOIT),
50 using caregiver-measured and administered doses of a supermarket food product, at inducing
51 desensitisation in children from 1-4 years of age when compared to standard care of strict
52 peanut avoidance.
53
54

55 Aims

56 57 **Primary objective**

To compare the proportion of participants with a peanut eliciting dose (ED) >600mg peanut protein in pOIT and control groups, as assessed by open peanut oral food challenge (OFC) at 12 months (end of treatment, EOT).

Secondary and exploratory objectives

To describe the safety of pOIT as assessed by parent-reported treatment-related adverse events and efficacy as assessed by range of EDs at EOT OFC; compare changes in quality of life and perception of OIT between groups and during course of pOIT; and describe treatment costs and immunological changes associated with pOIT.

Methods

Trial design

EPIC is a 2-armed, open-label, randomised controlled superiority trial of peanut oral immunotherapy (pOIT) compared to peanut avoidance (1:1 allocation).

pOIT = peanut OIT taken daily for 12 months

Control = peanut avoidance (standard care, no placebo)

Study setting

This is a single centre study conducted in a tertiary paediatric hospital (Perth Children's Hospital, Australia). Food challenges and initiation of OIT will be conducted on a day admission ward, and up-dosing visits will be conducted in outpatient clinic under the supervision of experienced nursing staff with medical support as required. Between study visits, pOIT will be administered daily by parents at home.

Participants

Fifty children from 1 to 4 years of age with confirmed or highly probable IgE-mediated peanut allergy will be enrolled.

Inclusion criteria

- 1) Age from 1-4 years
- 2) Confirmed or highly probable peanut allergy, defined as
 - a) Confirmed: positive peanut SPT (mean wheal diameter ≥ 3 mm) or specific IgE (>0.35 kU/L) and objective allergic reaction to screening peanut open food challenge
 - b) Highly probable:

- i) Unequivocal past clinical history of allergic reaction to peanut, and at least 1 of the following at screening: Peanut SPT mean wheal diameter at ≥ 8 mm ; Peanut sIgE >15 kU/L; Ara h 2 sIgE >1 kU/L, OR
- ii) Equivocal or no clinical history of allergic reaction to peanut, with at least 2 of the following at screening: Peanut SPT at screening ≥ 8 mm; Peanut sIgE >15 kU/L; Ara h 2 sIgE >1 kU/L

Exclusion criteria

- 1) History of severe, life-threatening anaphylaxis to peanut prior to enrolment.
- 2) Use of beta-blockers
- 3) Currently receiving any other allergen (food, venom, aeroallergen) immunotherapy, or have received food immunotherapy in the past 3 months.
- 4) Significant underlying medical conditions that increase risk of adverse outcomes in the event of an allergic reaction, such as severe cardiovascular or respiratory diseases.
- 5) Persistent, uncontrolled asthma or wheezing episodes.

Recruitment and consent

Potential participants will be referred from public and private allergy clinics or recruited from the community. Informed consent will be obtained in accordance with International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) and National Health and Medical Research Council (NHMRC) guidelines and documented using Research Electronic Data Capture (REDCap) software hosted on secure Western Australian Department of Health servers.

Blinding and Randomisation

Participants will be randomised to pOIT or standard care (peanut avoidance), stratified by confirmed or highly probable peanut allergy (as per inclusion criteria) and age (1-2 or 3-4 years old at enrolment).

This pragmatic study is unblinded with no placebo, reflecting current standard of care where the alternative to peanut OIT is peanut avoidance.

Intervention

Peanut OIT consists of incrementally increasing daily doses of defatted peanut flour (50% protein by weight, Peanut Butter & Co Pure Peanut powder, New York, USA). This is a commercially available food grade supermarket product that does not require any specialised manufacturing or handling.

Intervention (OIT) arm treatment protocol (see Table 1):

Treatment initiation: Participants receive up to 4 increasing doses every 20 minutes to reach a final dose of 15mg peanut protein. Doses are mixed with a small amount of a food of the participants' choice. If a participant has an allergic reaction during TI, the next day they commence pOIT dosing at home with the dose immediately below the one that provoked onset of symptoms (i.e. Dose 1-3). If all doses are tolerated during TI, participants commence pOIT at home with 15mg of nut protein (Dose 4). Any remaining doses not completed during TI will be incorporated into the up-dosing phase.

Participants' parents are provided with standard measuring spoons (1/64 to 1/4 teaspoons) to dispense daily treatment doses. A suspension of peanut powder in water is prepared by parents to administer doses ≤ 10 mg at home if required. Parents will receive training on use of measuring spoons and preparation of suspension (if required) during TI and up-dosing visits.

Up-dosing: Following TI participants continue the same dose at home daily for 2 weeks. Up-dosing to the next dose level occurs under clinical supervision in an outpatient setting, with 2 hours of observation post-dose. If the increased dose is tolerated, participants continue that dose at home; if there is an allergic reaction during the up-dosing visit, participants will restart the previously tolerated dose at home from the following day. Up-dosing will occur every 2 weeks (minimum 6 visits) until the target maintenance dose of 360mg peanut protein (3/8 tsp peanut powder) is reached.

Maintenance: Participants will continue to take daily doses of 3/8 tsp peanut flour until a total of 12 months of treatment is completed (calculated from date of TI visit). Participants can miss up to 2 non-consecutive doses per week to accommodate requirements of daily life (daycare, sports, school). Dose modifications may be made through this phase according to pre-specified criteria for moderate-severe treatment-related allergic reactions, intercurrent illnesses, or extended periods of missed doses.

Treatment Phase	Dose Level	Defatted peanut flour dose	Equivalent Peanut Protein	Interval prior to dose increase
Treatment Initiation (Single day if tolerated)	1	2mg	1 mg	N/A
	2	6mg	3 mg	20 min
	3	20mg	10 mg	20 min
	4	1/64 tsp	15 mg	2 weeks
Up-dosing	5	1/32 tsp	30 mg	2 weeks
	6	1/16 tsp	60 mg	2 weeks
	7	1/8 tsp	120 mg	2 weeks
	8	3/16 tsp	180 mg	2 weeks
	9	1/4 tsp	240mg	2 weeks
Maintenance	10	3/8 tsp	360mg	Until 52 weeks total treatment

Table 1: Peanut OIT dosing schedule

Control (standard care) arm

Continued strict avoidance of peanut for 12 months from the date of randomisation.

Primary outcome

Proportion of participants with a peanut eliciting dose > 600mg peanut protein at end of treatment in pOIT vs control, as assessed by open peanut OFC. The primary outcome will be assessed by conducting a peanut OFC with peanut at end of treatment, defined as 12 months after Treatment Initiation in the pOIT group and 12 months after randomisation in the control group.

Secondary outcomes

Patient-reported outcomes

- Proportion of participants reporting, severity of, and frequency of, treatment-related adverse events
- Change in child (Food Allergy Quality of Life Questionnaire – Parent Form, FAQLQ-PF) and parent (Food Allergy Quality of Life – Parental Burden, FAQL-PB) quality of life and parent food allergy self-efficacy (Food Allergy Self-Efficacy for Parents, FASE-P) from baseline to EOT

Other secondary outcomes

- Proportion of participants discontinuing peanut OIT treatment
- Change in peanut specific IgE and peanut SPT wheal size from baseline to EOT
- Proportion of participants with (a) eliciting dose ≥ 300 mg, (b) eliciting dose ≥ 600 mg, and (c) no allergic reaction to 2500mg peanut protein dose at EOT

Exploratory outcomes

Patient-reported

- Change in quality of life and parent self-efficacy during pOIT (baseline vs 12 weeks and 24 weeks; 12 weeks and 24 weeks vs EOT)
- Parental perceptions of OIT before, during and after treatment, as assessed by Net Promoter Score (NPS) and Patient Experience Survey (PES)

Other exploratory outcomes

- Baseline characteristics associated with successful desensitisation following pOIT
- Changes in peanut SPT and sIgE in responders and non-responders to pOIT
- Changes in other immune parameters (humoral, RNA/protein expression, cellular phenotype) associated with pOIT
- Treatment-associated costs of pOIT

Study procedures

The Schedules of Procedures are summarised in Tables 2 (Intervention) and 3 (Control).

Baseline assessment

Demographics, personal and family history of atopic disease including participant history of allergic reactions to peanut and other medical history.

Eczema will be assessed using the SCORing of Atopic Dermatitis (SCORAD) scoring index[23].

Medications

Beta-blockers, anti-IgE monoclonal antibodies and any other form of allergen immunotherapy will be prohibited.

All participants will be prescribed an adrenaline autoinjector and ASCIA Action Plan for Anaphylaxis.

Biospecimen collection

Blood: Venous blood will be drawn in lithium heparin and serum vacutainer tubes. Peanut and Ara h 2 serum sIgE will be measured by ImmunoCAP (Phadia AB, Uppsala, Sweden). Whole blood will be separated for frozen storage of aliquots peripheral blood mononuclear cells (stored in liquid nitrogen), plasma and serum (stored at -80 degrees C).

Stool: Samples will be collected at baseline and EOT using OMNIgene GUT kit.

Saliva: Saliva samples will be collected using a cotton swab, centrifuged and frozen.

Skin Prick Test (SPT)

Peanut extract (ALK USA) plus negative saline and positive histamine control SPT will be conducted on the forearm of each participant, using Quintips. The average of the longest wheal diameter (D1) and the longest perpendicular measurement to D1 will be recorded as the mean wheal diameter.

Quality of Life (QoL) and Parental Perception Questionnaires

The FAQLQ and FAQL-PB are disease specific health-related QoL for children with food allergy[24] and their parents.[25] The Food Allergy Self-Efficacy for Parents (FASE-P) is a validated questionnaire to assess parental confidence in managing food allergy.[26] QoL will be measured using FAQLQ-PF,[27] FAQL-PB and FASE-P completed by the same parent throughout.

1
2
3 Parental perceptions of OIT will be measured using NPS, a widely used customer experience
4 metric that has been used to assess patient satisfaction with health services.[28]
5
6

7 The Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional
8 Distress Anxiety Short Form 8a[29, 30] and the Parent Proxy Short Form 8a[31]
9 questionnaires are validated person-centred measures for anxiety in individuals and their
10 children. Parents will complete this questionnaire once at EOS.
11
12

13 The PES is derived from the Australian Hospital Patient Experience Question Set[32]
14 developed by the Australian Commission on Safety and Quality in Health Care, modified to
15 suit the trial setting and with additional questions included based on feedback from consumer
16 consultation prior to the trial.
17
18

19 20 **Daily Diary** 21

22 Parents will complete a web-based daily electronic diary directly into REDCap. Diary data
23 will be used to assess adherence, AEs, accidental peanut ingestion and hospital admissions.
24 Control group will complete a daily diary during Month 3 and Month 9 to collect background
25 rates of parent-reported AEs.
26
27

28 29 **Oral food challenge** 30

31 An open peanut OFC will be performed at study entry for those participants who do not meet
32 the criteria for “highly probable peanut allergy”, and in all participants at end of treatment. The
33 OFC will be conducted using an adaptation of the ASCIA peanut challenge protocol, modified
34 to include an additional 600mg dose step resulting in increments of 10mg, 30mg, 100mg,
35 300mg, 600mg, 1000mg and 2500mg peanut protein given at 20-minute intervals.
36
37

38 Positive challenges will be defined by an allergic reaction meeting PRACTALL consensus
39 stopping criteria[33] with severity assessed in accordance with published multidisciplinary
40 expert consensus guidelines.[34] The eliciting dose (ED) is defined as the amount of peanut
41 protein in the OFC dose given immediately prior to onset of signs meeting stopping criteria.
42
43

44 45 **Statistical analysis plan** 46

47 48 Sample size 49

50 A sample size of 50 randomised participants allocated 1:1 to pOIT (n=25) or control (n=25)
51 will have power of 0.85 to detect a difference in proportion achieving the primary outcome of
52 66% in pOIT and 25% in control with an alpha of 0.05. Recruitment and randomisation of the
53 target participant sample size has been completed. The study is ongoing, with completion of
54 data collection anticipated to be completed in January 2024.
55
56
57
58
59
60

1
2
3 Baseline assumptions of pOIT efficacy were derived from published registry data of
4 preschool pOIT outcomes[35] and a phase III RCT of peanut OIT in 4-17-year-olds.[36] The
5 estimated 25% response rate in controls includes participants with naturally high (>600mg
6 peanut protein) reaction threshold, spontaneous resolution of allergy, or rarely
7 misclassification at baseline of a non-allergic participant as having “highly probable” peanut
8 allergy, noting that those with relatively low sIgE and SPT would not be eligible for
9 enrolment in this study based without undergoing an OFC at entry to confirm peanut allergy.
10
11
12

13 Outcome analysis

14
15
16 Continuous variables will be presented as mean and standard deviations or medians and
17 interquartile ranges depending on distribution of data. For count data rates will be reported,
18 while categorical variables will be presented as frequencies and proportions. For exploratory
19 variables statistical analyses will be hypothesis generating to inform future studies.
20
21
22

23 Alpha will be set at 0.05, and 95% confidence intervals (CIs) reported unless otherwise
24 specified. We will perform between group comparisons for each primary and secondary
25 outcome at the end of the study at 12 months. Efficacy will be determined by comparing
26 differences between groups using a Chi Square test or a Fishers Exact test (if expected cell
27 counts <5), with difference in proportions reported. Odds ratios will be produced via logistic
28 regression, with adjustment for potential confounders. Secondary outcomes with continuous
29 data (peanut SPT wheal size and sIgE) will be analysed using Student t-tests or Mann-Whitney
30 U test depending on distribution.
31
32
33

34
35 Adverse events will be presented in frequency tables. Exposure-adjusted incidence of
36 treatment-related AEs will be calculated by dividing total trAEs by total pOIT doses taken over
37 a specified period.
38
39

40 Analysis will primarily be on all consented participants in an intention-to-treat analysis. Per-
41 protocol analysis will include only children who complete the study as per the protocol.
42 Deidentified data will be used for outcome analysis.
43
44

45 No interim analysis is planned.
46
47

48 **Research Ethics Approval**

49
50 The study has been reviewed by the Child and Adolescent Health Service HREC (RGS 4384).
51
52

53 **Study oversight, registration, funding, consumer involvement and dissemination**

54
55
56 A consumer reference group comprising parents of preschool aged children with peanut allergy
57 were consulted when developing the study protocol.
58
59

60 The Child and Adolescent Health Service will be the study Sponsor.

1
2
3
4 The trial was prospectively registered with the Australia New Zealand Clinical Trials Registry
5 (ACTRN12621001001886).
6
7

8 An independent data and safety monitoring committee (DSMC) will be comprised of a
9 biostatistician, and two clinical immunologists who have no conflicts of interest with this study.
10
11

12 This work is supported by the Government of Western Australia Department of Health and
13 Channel 7 Telethon Trust through the WA Child Research Fund. The funders have no role in
14 the study design, conduct or analysis.
15
16

17 Results will be published in a peer-reviewed journal and presented at national scientific
18 meetings using grouped and deidentified data only. A consumer reference group, comprising
19 parents of preschool aged children with peanut allergy, were consulted when developing the
20 study protocol and will inform the plan for dissemination of outcomes to participants and the
21 community.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PEANUT OIT; Intervention Group							
Study phase	Screening		Treatment			End of treatment	End of Study
Week of study	Up to -24		0	2 to 12	16 to 48	52 (up to 56)	+4 from EOT
Visit category	Screening visit	Entry OFC	Initiation	Up-dosing	Maintenance	Exit OFC	
Duration	2 hours	5-6 hours	4 hours	2-3 hours	15 mins remote	5-6 hours	15min remote
Procedure							
Informed consent	X						
Eligibility criteria	X	X	X				
Demographics, medical and family history	X						
Anthropometrics, vital signs, physical exam, SCORAD	X	X	X	X		X	
Questionnaires	X			X - 12 weeks	X - 24 weeks		X
Skin prick test	X					X	
Blood, stool and saliva samples	X	(X)		X - 12 weeks		X	
Oral food challenge		X				X	
Adverse event, concomitant medication assessment		X	X	X	X	X	X
Anaphylaxis education		X	X	X		X	
OIT doses at site			X	X			
OIT dosing education			X	X			

Table 2: Summary of schedule of procedures for intervention group

PEANUT OIT; Intervention Group					
Study phase	Screening		Standard care	End of treatment	End of Study
Week of study	Up to -24		0-52	52 (up to 56)	+4 from EOT
Visit category	Screening visit	Entry OFC	Telephone contact every 3 months	Exit OFC	
Duration	2 hours	5-6 hours	15 mins remote	5-6 hours	15min remote
Procedure					
Informed consent	X				
Eligibility criteria	X	X			
Demographics, medical and family history	X				
Anthropometrics, vital signs, physical exam, SCORAD	X	X		X	
Questionnaires	X		X - 12 weeks and 24 weeks		X
Skin prick test	X			X	
Blood, stool and saliva samples	X	(X)		X	
Oral food challenge		X		X	
Adverse event, concomitant medication assessment		X	X	X	X
Anaphylaxis education		X		X	
Strict peanut avoidance			X		

Table 3: Summary of schedule of procedures for control group

References

1. Osborne NJ, Koplin JJ, Martin PE, et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. *J Allergy Clin Immunol* 2011; **127**(3): 668-76.
2. Peters RL, Allen KJ, Dharmage SC, et al. Natural history of peanut allergy and predictors of resolution in the first 4 years of life: A population-based assessment. *J Allergy Clin Immunol* 2015; **135**(5): 1257-66 e1-2.
3. Peters RL, Koplin JJ, Gurrin LC, et al. The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up. *J Allergy Clin Immunol* 2017; **140**(1): 145-53.e8.
4. Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA. The natural history of peanut allergy. *J Allergy Clin Immunol* 2001; **107**(2): 367-74.
5. Mullins RJ, Wainstein BK, Barnes EH, Liew WK, Campbell DE. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. *Clinical & Experimental Allergy* 2016; **46**(8): 1099-110.
6. Avery NJ, King RM, Knight S, Hourihane JO. Assessment of quality of life in children with peanut allergy. *Pediatr Allergy Immunol* 2003; **14**(5): 378-82.
7. Venter C, Sommer I, Moonesinghe H, et al. Health-related quality of life in children with perceived and diagnosed food hypersensitivity. *Pediatr Allergy Immunol* 2015; **26**(2): 126-32.
8. Thörnqvist V, Middelveld R, Wai HM, et al. Health-related quality of life worsens by school age amongst children with food allergy. *Clinical and Translational Allergy* 2019; **9**(1): 10.
9. Lieberman JA, Gupta RS, Knibb RC, et al. The global burden of illness of peanut allergy: A comprehensive literature review. *Allergy* 2021; **76**(5): 1367-84.
10. Soriano VX, Peters RL, Moreno-Betancur M, et al. Association Between Earlier Introduction of Peanut and Prevalence of Peanut Allergy in Infants in Australia. *JAMA* 2022; **328**(1): 48.
11. Tang MLK, Mullins RJ. Food allergy: is prevalence increasing? *Internal Medicine Journal* 2017; **47**(3): 256-61.
12. Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. *J Allergy Clin Immunol* 2017; **139**(1): 173-81 e8.
13. Tang ML, Ponsonby AL, Orsini F, et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. *J Allergy Clin Immunol* 2015; **135**(3): 737-44 e8.
14. Investigators PGoC, Vickery BP, Vereda A, et al. AR101 Oral Immunotherapy for Peanut Allergy. *N Engl J Med* 2018; **379**(21): 1991-2001.
15. de Silva D, Rodriguez Del Rio P, de Jong NW, et al. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis. *Allergy* 2022; **77**(6): 1852-62.
16. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. *Lancet* 2019; **393**(10187): 2222-32.
17. Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. *The Lancet* 2022; **399**(10322): 359-71.

18. Loke P, Orsini F, Lozinsky AC, et al. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. *Lancet Child Adolesc Health* 2022; **6**(3): 171-84.
19. Remington BC, Krone T, Kim EH, et al. Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy. *Annals of Allergy, Asthma & Immunology* 2019; **123**(5): 488-93.e2.
20. Australasian Society of Clinical Immunology and Allergy. Position Paper - Oral Immunotherapy for Food Allergy, 2023. Available at <https://www.allergy.org.au/hp/papers/ascia-oral-immunotherapy-for-food-allergy> [Accessed 17 July 2023].
21. Muraro A, De Silva D, Halken S, et al. Managing food allergy: GA2LEN guideline 2022. *World Allergy Organization Journal* 2022; **15**(9): 100687.
22. Bégin P, Chan ES, Kim H, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. *Allergy Asthma Clin Immunol* 2020; **16**: 20.
23. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. *Dermatology* 1997; **195**(1): 10-9.
24. Cohen BL, Noone S, Muñoz-Furlong A, Sicherer SH. Development of a questionnaire to measure quality of life in families with a child with food allergy. *J Allergy Clin Immunol* 2004; **114**(5): 1159-63.
25. Knibb RC, Stalker C. Validation of the Food Allergy Quality of Life-Parental Burden Questionnaire in the UK. *Qual Life Res* 2013; **22**(7): 1841-9.
26. Knibb RC, Barnes C, Stalker C. Parental confidence in managing food allergy: development and validation of the Food Allergy Self-Efficacy Scale for Parents (FASE-P). *Clin Exp Allergy* 2015; **45**(11): 1681-9.
27. Dunngalvin A, De Blokfloksstra BMJ, Burks AW, Dubois AEJ, Hourihane JOB. Food allergy QoL questionnaire for children aged 0–12 years: content, construct, and cross-cultural validity. *Clin Exp Allergy* 2008; **38**(6): 977-86.
28. Alismail A, Schaeffer B, Oh A, et al. The Use of the Net Promoter Score (NPS) in an Outpatient Allergy and Pulmonary Clinic: An Innovative Look into Using Tablet-Based Tool vs Traditional Survey Method. *Patient Related Outcome Measures* 2020; **Volume 11**: 137-42.
29. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. *Journal of Clinical Epidemiology* 2010; **63**(11): 1179-94.
30. Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D. Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS®): Depression, Anxiety, and Anger. *Assessment* 2011; **18**(3): 263-83.
31. Irwin DE, Gross HE, Stucky BD, et al. Development of six PROMIS pediatrics proxy-report item banks. *Health and Quality of Life Outcomes* 2012; **10**(1): 22.
32. Australian Commission on Safety and Quality in Health Care. Australian Hospital Patient Experience Question Set. 2019. Available at <https://www.safetyandquality.gov.au/our-work/indicators-measurement-and-reporting/australian-hospital-patient-experience-question-set> [Accessed 17 July 2023]
33. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma &

1
2
3 Immunology-European Academy of Allergy and Clinical Immunology PRACTALL
4 consensus report. *J Allergy Clin Immunol* 2012; **130**(6): 1260-74.

5 34. Dribin TE, Schnadower D, Spergel JM, et al. Severity grading system for acute
6 allergic reactions: A multidisciplinary Delphi study. *J Allergy Clin Immunol* 2021; **148**(1):
7 173-81.

8 35. Soller L, Abrams EM, Carr S, et al. First Real-World Effectiveness Analysis of
9 Preschool Peanut Oral Immunotherapy. *J Allergy Clin Immunol Pract* 2021; **9**(3):1349-1356.

10 36. The PALISADE Group of Clinical Investigators. AR101 Oral Immunotherapy for
11 Peanut Allergy. *N Engl J Med* 2018; **379**(21): 1991-2001.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60